Hope for Hard-to-Treat lung infection: old drug shows promise
NCT ID NCT02968212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called clofazimine for people with a chronic lung infection caused by Mycobacterium avium complex (MAC). The goal is to see if adding clofazimine to standard treatment helps clear the bacteria from sputum and improves walking ability and fatigue. About 102 adults with confirmed MAC lung disease are taking part. The drug is not a cure, but aims to better control the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Louisiana State University
Baton Rouge, Louisiana, 70803, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of South Florida
Tampa, Florida, 33620, United States
-
University of Texas Health Science Center
Tyler, Texas, 75708, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.